ipilimumab,nivolumab,cabozantinib
exelixis,bms
['cosmic-313']
cosmic-313:met it s primary endpoint of pfs (median not reached yet!) now the new question we have to answer is not which doublet, but triple or double and for whom? #esmo22 
Pursuing to improve cancer prevention and care. Medical Oncologist @AnkaraUni